SCHEMBL8225435

SCHEMBL8225435

NNCc1cccc(Cl)c1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 2/20 0.42
HTT P42858 1/20 0.41
P2RX7 Q99572 4/20 0.41
CD38 P28907 1/20 0.40
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
MPO P05164 1/20 0.38
TAAR1 Q96RJ0 3/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP1A2 P05177 1/20 0.38
GLA P06280 1/20 0.38
IDO1 P14902 2/20 0.37
AKR1B1 P15121 1/20 0.37
CFD P00746 1/20 0.37
MEN1 O00255 1/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL15066404 0.98 HTT (0.44) PNMTHTTP2RX7CD38ALDH1A1
SCHEMBL28046920 0.80 P2RX7 (0.48) P2RX7CD38ALDH1A1MAPTCFD
SCHEMBL13886573 0.80 SLC6A2 (0.47) HTTP2RX7CD38ALDH1A1TAAR1
SCHEMBL16385710 0.80 HTT (0.41) PNMTHTTP2RX7CD38ALDH1A1
SCHEMBL6068499 0.79 MAPT (0.41) HTTP2RX7ALDH1A1GAAMAPT
SCHEMBL8224664 0.79 PNMT (0.61) PNMTP2RX7ALDH1A1GAAMAPT
SCHEMBL6068451 0.79 PNMT (0.56) PNMTHTTALDH1A1GAAMAPT
SCHEMBL559225 0.79 PNMT (0.67) PNMTMPOTAAR1CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL6252762 0.78 SLC6A2 (0.46) HTTP2RX7CD38ALDH1A1TAAR1
SCHEMBL23368473 0.78 MEN1 (0.48) HTTP2RX7CD38ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713985-B2 Adenosine Aa2 receptor antagonists SCHERING CORPORATION (US) 2010-05-11 US disclosed
US-7713985-B2 Adenosine Aa2 receptor antagonists SCHERING CORPORATION (US) 2010-05-11 US disclosed
EP-2038285-B1 ADENOSINE A2A RECEPTOR ANTAGONISTS SCHERING CORP (US) 2010-02-17 EP disclosed
US-20080255156-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2008-10-16 US disclosed
US-20080255156-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2008-10-16 US disclosed
WO-2008002596-A2 ADENOSINE A2A RECEPTOR ANTAGONISTS SCHERING CORPORATION (US) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255156-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS ADORA3, ADORA2A, ADORA1 PNMT 1978/4885HTT 876/4885P2RX7 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.